M D Anderson Cancer Center Prosate SPORE

MD 安德森癌症中心前列腺孢子

• 批准号: 8321890
• 负责人: Christopher J. Logothetis
• 金额: $ 230万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-02 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8321890
• 关键词: Address; Apoptotic; Basic Science; Bioinformatics; Biological Markers; Biometry; Cancer Center; Clinical Trials; Combined Modality Therapy; Dasatinib; Development; Disease; Doctor of Medicine; Epidemiology; Fibroblast Growth Factor; Funding; Goals; Incidence; Leadership; Ligands; Malignant neoplasm of prostate; Molecular; Morbidity - disease rate; Obesity; Patients; Peptides; Population Sciences; Principal Investigator; Prostate; Research; Research Infrastructure; Research Project Grants; Signal Transduction; Specimen; Testing; Therapeutic; Therapeutic Agents; Translating; Translational Research; Virulent; Work; ataxia telangiectasia mutated protein; career development; clinical practice; docetaxel; effective therapy; inhibitor/antagonist; innovation; mortality; novel; novel therapeutics; programs; research clinical testing; response; tool

Through this application M. D. Anderson Cancer Center seeks funding for a new Prostate Cancer SPORE. Under the leadership of Dr. Christopher J. Logothetis, Principal Investigator, and Dr. Timothy C. Thompson, Co-Principal Investigator, who are recognized internationally for their research in prostate cancer, the M. D. Anderson Cancer Center Prostate SPORE has created a stable and dynamic infrastructure for translational research that works toward the development of non-morbid therapies for patients with localized prostate cancer; the identification of predictive biomarkers for therapeutic response; the development of new biologically targeted therapeutic agents; and the linkage of epidemiological and molecular signaling profiles for virulent prostate cancer. We continue to build on our capacity to conduct novel and innovative clinical trials and believe that new research projects conducted by our translational research team will yield substantial progress and meaningful changes in clinical practice. In the current proposal we define our translational research objectives as (1) development of quantitative tools for determination of aggressive prostate cancers; (2) testing of novel therapeutic agents in proof of principle clinical trials; (3) development of predictive biomarkers for identification of patients who will respond to targeted therapies; and (4) development of rational strategies for combination therapies. We will achieve these translational research objectives by identifying and testing obesity-related biomarkers for virulent prostate cancer, clinical testing of GLIPR1-ATM protein and a novel ligand-directed pro-apoptotic peptide (BMTP-11) for prostate cancer, and conducting two hypothesis-driven clinical trials with a novel FGF signaling inhibitor (TKl 258), and combination Src inhibitor (Dasatinib)+Docetaxel in patients with advanced prostate cancer. We will accomplish our goals through 5 research projects (including one population science research project), 3 support cores (Administrative, Biostatistics and Bioinformatics, and Specimen), a dynamic Developmental Research Program and an effective Career Development Program. We are optimistic that our research efforts will contribute to reductions in the incidence of, and morbidity and mortality from, this devastating disease by translating basic research into clinical practice.

通过这个应用程序M。D.安德森癌症中心为一个新的前列腺癌孢子寻求资金。在主要研究者Christopher J. Logothetis博士和Timothy C.博士的领导下，汤普森，共同首席研究员，谁是国际公认的他们的研究在前列腺癌，M。D.安德森癌症中心前列腺孢子创造了一个稳定和动态的基础设施转化研究，致力于发展非病态疗法的患者局限性前列腺癌;预测生物标志物的治疗反应的鉴定;新的生物靶向治疗药物的开发;和流行病学和分子信号转导谱的链接恶性前列腺癌。我们将继续加强我们进行新颖和创新临床试验的能力，并相信我们的转化研究团队进行的新研究项目将在临床实践中取得实质性进展和有意义的变化。 在目前的提案中，我们将我们的转化研究目标定义为（1）开发用于确定侵袭性前列腺癌的定量工具;（2）在原理性临床试验中测试新型治疗药物;（3）开发用于识别对靶向治疗有反应的患者的预测性生物标志物;（4）开发联合治疗的合理策略。 我们将通过鉴定和测试恶性前列腺癌的肥胖相关生物标志物、前列腺癌的GLIPR 1-ATM蛋白和新型配体导向的促凋亡肽（BMTP-11）的临床测试以及用新型FGF信号传导抑制剂（TK 1258）进行两项假设驱动的临床试验来实现这些转化研究目标，以及Src抑制剂（达沙替尼）+多西他赛联合治疗晚期前列腺癌患者。 我们将通过5个研究项目（包括一个人口科学研究项目），3个支持核心（行政，生物统计学和生物信息学，标本），一个动态的发展研究计划和一个有效的职业发展计划来实现我们的目标。我们乐观地认为，我们的研究工作将有助于通过将基础研究转化为临床实践，减少这一毁灭性疾病的发病率、发病率和死亡率。